R7128 Received Fast-track Status from FDA

The US Food and Drug Administration has given Pharmasset Inc.'s (NASDAQ:VRUS) R7128 a fast-track status in order to make the drug become more available to individuals who are chronically infected with Hepatitis C Virus. CNN has the story.

Vaccine for Hepatitis C is not yet available and just like Hepatitis B, Hepatitis C can cause liver damage such as cirrhosis and cancer.

According to Centers for Disease Control and Prevention (CDC) that, "you may be at risk for hepatitis C and should contact your medical care provider for a blood test if you:

* were notified that you received blood from a donor who later tested positive for hepatitis C.
* have ever injected illegal drugs, even if you experimented a few times many years ago
* received a blood transfusion or solid organ transplant before July, 1992
* were a recipient of clotting factor(s) made before 1987
* have ever been on long-term kidney dialysis
* have evidence of liver disease (e.g., persistently abnormal ALT levels)

Please visit Centers for Disease Control and Prevention for more information about Hepatitis C virus.